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OBJECTIVES We aimed to determine whether long QT syndrome (LQTS) genotype has a differential effect
on clinical course of disease in male and female children and adults after adjustment for QTc
duration.
BACKGROUND Genotype influences clinical course of the LQTS; however, data on the effect of age and
gender on this association are limited.
METHODS The LQTS genotype, QTc duration, and follow-up were determined in 243 cases of LQTS
caused by the KCNQ1 potassium channel gene mutations (LQT1), 209 cases of LQTS
caused by the HERG potassium channel gene mutations (LQT2), and 81 cases of LQTS
caused by the SCN5A sodium channel gene mutation (LQT3) gene carriers. The probability
of cardiac events (syncope, aborted cardiac arrest, or sudden death) was analyzed by genotype,
gender, and age (children  15 years and adults 16 to 40 years). In addition, the risk of
sudden death and lethality of cardiac events were evaluated in 1,075 LQT1, 976 LQT2, and
324 LQT3 family members from families with known genotype.
RESULTS During childhood, the risk of cardiac events was significantly higher in LQT1 males than in
LQT1 females (hazard ratio [HR]  1.72), whereas there was no significant gender-related
difference in the risk of cardiac events among LQT2 and LQT3 carriers. During adulthood,
LQT2 females (HR  3.71) and LQT1 females (HR  3.35) had a significantly higher risk
of cardiac events than respective males. The lethality of cardiac events was highest in LQT3
males and females (19% and 18%), and higher in LQT1 and LQT2 males (5% and 6%) than
in LQT1 and LQT2 females (2% for both).
CONCLUSIONS Age and gender have different, genotype-specific modulating effects on the probability of
cardiac events and electrocardiographic presentation in LQT1 and LQT2 patients. (J Am
Coll Cardiol 2003;42:103–9) © 2003 by the American College of Cardiology Foundation
The long QT syndrome (LQTS) is a familial disorder
characterized by prolonged ventricular repolarization and a
propensity for torsades de pointes leading to syncope and
sudden death (1–3). Mutations in genes encoding potassium
and sodium cardiac ion channel genes have been found to
cause distinct forms of LQTS (4–6). The clinical course of
LQTS is influenced by genotype (6,7). The LQT1 patients,
carrying KCNQ1 potassium channel (IKs) gene mutation,
and LQT2 patients, with HERG potassium channel (IKr)
gene mutation, have a higher risk of cardiac events occurring
throughout their lifetime than LQT3 patients carrying the
SCN5A sodium channel (INa) gene mutation (6). How-
ever, LQT3 patients have a higher lethality of cardiac events
than LQT1 and LQT2 patients (6). Our previous observa-
tions (8,9) also indicated that cardiac events tend to occur
more frequently in childhood (age 16 years) with LQTS
males having a higher risk and earlier onset of events than
females. In adulthood (age 16 to 40 years), although the risk
of cardiac events is decreasing, there is a gender-related
difference: female LQTS patients experience more events
than males (8,9). Age- and gender-related differences in
QTc duration have been observed both in healthy subjects
(10) and in LQTS patients (11); LQTS genotype has also
been shown to influence QT interval duration and repolar-
ization (T-wave) morphology (11–13). The above observa-
tions indicate that a complex relationship between geno-
type, age, gender, and QTc duration may influence the
clinical course of the disease in LQTS patients, with
possible modulating effects of age and gender on gene-
specific clinical presentation. Our initial efforts to investi-
gate this complex age-gender-genotype relationship were
limited by the relatively small number of genotyped indi-
viduals (6,9). Presently, we have greatly expanded the
patient cohort, which allows us to investigate whether
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LQTS genotype has a differential effect on the clinical
course of disease in male and female children, and adults,
after adjustment for QTc duration.
METHODS
Study population. The study population described in this
paper is an outgrowth of ongoing data collection by the
International Long QT Syndrome Registry (1). The LQTS
genotype was determined in 533 patients: 243 LQT1 gene
carriers with the KCNQ1 mutations from 53 families, 209
LQT2 gene carriers with the HERG mutations from 61
families, and 81 LQT3 gene carriers with the SCN5A
mutations from 9 families. Table 1 shows the breakdown of
studied patients by genotype, gender, and age at last
follow-up before cardiac event or initiation of beta-blocker
treatment. The initiation of beta-blocker therapy was used
as a censoring point to enable the analysis of the natural
course of LQTS, that is, without influence of beta-blockers.
The effectiveness of beta-blockers in LQTS was recently
evaluated by our group (14) and, therefore, is not the subject
of this analysis. The choice of age categories (children from
0 to15 years and adults from 16 to 40 years) was based on
our previous observation that risk of cardiac events may
change after age 15 years (8,9). When analyzing the risk of
cardiac events in children, all gene carriers with known QTc
measurements and follow-up counted until age 15 were
included. When evaluating the risk of cardiac events in
adults, all LQTS gene carriers with recorded electrocardio-
grams (ECGs) who survived to age 16 without cardiac event
and without beta-blocker treatment were included. There-
fore, the children’s group included all studied carriers,
whereas in the adult group, carriers with cardiac events or
beta-blocker treatment before 16 were excluded.
In addition to gene carriers, we also evaluated cardiac
events in all directly related family members of genotyped
LQTS carriers (without requiring a recorded ECG or
genotyping) to determine the risk of sudden death and
lethality of cardiac events, unbiased by QTc duration or
access to genetic testing. Directly related family members
were defined as those family members who were on the side
of a family tree where LQTS was genetically confirmed, for
example, in the case of disease inherited from the mother,
only the maternal part of a family was included in the
analysis. There were 1,075 such family members (including
243 carriers) from LQT1 families, 976 family members
(including 209 carriers) from LQT2 families, and 324
family members (including 81 carriers) from LQT3 fami-
lies.
ECG parameters. The first recorded ECGs (regardless of
age) were routinely used to determine heart rate and the
Bazett-corrected QTc interval. Because in two-thirds of
carriers the first ECG was recorded after age 15, we
analyzed QTc duration by genotype and gender, using
ECGs recorded at age 0 to 15 and 16 to 40 years
separately. This analysis was also performed while excluding
probands, to diminish potential bias introduced by the
definition of probands (requiring QTc  440 ms).
Cardiac events. Cardiac events were defined as syncope,
aborted cardiac arrest (requiring defibrillation), or sudden
cardiac death, whichever occurred first. Cardiac events
occurring before initiation of beta-blocker therapy were
considered as the primary end point to avoid confounding
influence of these drugs on the probability of cardiac events.
The analysis of first cardiac event as an end point, regardless
of beta-blocker use, was also performed. To limit the
potential confounding effect of coronary artery disease on
the outcome of studied patients, only cardiac events occur-
ring by age 40 years were considered. In addition, we
analyzed the risk of recurrent cardiac events (at least two
cardiac events) and cardiac event rates per patient per year in
studied LQTS carriers.
In family members, we compared the occurrence of death
in males versus females by genotype and gender in age-
Abbreviations and Acronyms
HR  hazard ratio
IKr  HERG potassium channel
IKs  KCNQ1 potassium channel
INa  SCN5A sodium channel
LQTS  long QT syndrome
LQT1  long QT syndrome caused by the KCNQ1
potassium channel gene mutations
LQT2  long QT syndrome caused by the HERG
potassium channel gene mutations
LQT3  long QT syndrome caused by the SCN5A
sodium channel gene mutation
Table 1. Number and Follow-Up of LQTS Gene Carriers by Gender and Age*
LQT1 LQT2 LQT3
Males Females Males Females Males Females
Age 15 yrs
Number of carriers 108 135 88 121 42 39
Mean  SD follow-up (yrs)* 12  5 14  4 13  5 14  4 13  5 13  5
Age 16–40 yrs
Number of carriers 34 68 43 76 27 26
Mean  SD follow-up (yrs)* 20  8 18  8 19  8 15  9 17  9 17  8
*Follow-up age counted until time to beta-blocker treatment, or age 16 (for younger age group analyzed). By definition, subjects
age 16–40 years had to survive until age 16 without cardiac events and without beta-blocker treatment.
LQTS  long QT syndrome. Other abbreviations as in Abbreviations box.
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specific subgroups. Lethality of cardiac events, defined as
the number of deaths divided by the total number of cardiac
events (6), was compared between males and females by
gender in genotype groups. These analyses were performed
for cardiac events occurring before beta-blocker treatment.
Statistical analysis. To compare characteristics of males
and females within genotype, Welsh t tests and Wilcoxon
rank-sum tests were used for continuous variables, and
chi-square tests were used for binary variables. The distri-
butions of time to first cardiac event, stratified by genotype,
gender, and age were estimated using the Kaplan-Meier
method. For the analysis of children, birth was used as the
time origin, whereas for event-free adults, age 16 was
considered as the time origin. Stratified Cox proportional
hazards models, allowing for separate baseline hazard func-
tions for each genotype, were used to model the conditional
relationships of gender with time to first cardiac event
within each genotype and age group, adjusted for QTc at
first ECG (regardless of age at ECG). In order to make the
assumptions of proportional hazards plausible, separate Cox
models were fit for children, ignoring follow-up beyond age
16, and adults who survived to age 16 without events (or
beta-blocker therapy). Grouped jackknife estimates of stan-
dard errors were used to adjust p values and confidence
intervals for within-family dependence not directly modeled
by the stratified Cox models (15).
RESULTS
ECG characteristics of LQTS carriers. Table 2 shows
off-beta-blocker RR and QTc values from ECGs recorded
during specific age periods (well matched for age among
males and females) for LQTS carriers while excluding
probands. In childhood, LQT3 males had a higher QTc
duration and lower heart rate than LQT3 females, whereas
there was no gender difference in QTc duration and heart
rate among LQT1 and LQT2 carriers. In LQT1 adults,
there was no gender difference in QTc and heart rate,
whereas LQT2 females had significantly longer QTc and
somewhat faster heart rate than LQT2 males; LQT3 adult
males had a longer QTc and slower heart rate than adult
LQT3 females.
When comparing by age within gender-genotype sub-
groups, the QTc duration was longer in LQT1 children
than in LQT1 adults regardless of gender. There was no
such age-related difference in LQT2 males, whereas LQT2
and LQT3 females had QTc longer in adulthood than in
childhood.
Cardiac events in LQTS carriers age <15 years. There
were 165 patients with first cardiac event before beta-
blocker treatment among 533 LQTS carriers age15 years.
Figure 1 shows the cumulative probability of a first cardiac
event in female versus male LQTS carriers age15 years by
genotype, and the left panel of Table 3 shows hazard ratios
(HR) for females versus males, adjusted for QTc duration,
in the same groups. There was a significantly lower risk of
cardiac events in LQT1 females than in LQT1 males
(HR  0.58; p  0.005). In LQT2 and LQT3 children,
there was no significant difference between male and female
carriers. When comparing by genotype, the cumulative
probability of a first cardiac event by age 15 years was 56%
in LQT1 males, 42% in LQT1 females, 33% in LQT2
males, 27% in LQT2 females, and 6% to 8% in LQT3 males
Table 2. Clinical Characteristics of LQTS Carriers by Genotype and Gender
LQT1 LQT2 LQT3
Males
(n  108)
Females
(n  135)
Males
(n  88)
Females
(n  121)
Males
(n  42)
Females
(n  39)
ECG parameters†
Age 15 yrs n  34 n  31 n  22 n  16 n  16 n  12
Age at ECG (yrs) 6  4 7  5 6  6 8  6 6  5 5  5
RR (ms) 717  177 730  206 638  185 649  137 804  304 613  179
QTc (ms) 490  45 487  35 477  30 475  56 528  45 469  43*
Age 16–40 yrs n  14 n  27 n  20 n  32 n  14 n  15
Age at ECG (yrs) 28  9 29  8 30  8 27  8 26  8 26  8
RR (ms) 921  209 909  169 932  187 878  127 1,146  291 852  148*
QTc (ms) 469  22 473  31 466  34 490  45* 515  48 499  32
Cardiac events
Carriers with 1 cardiac event 55 (51%) 72 (53%) 30 (34%) 62 (51%)* 7 (17%) 7 (18%)
Median age at 1st cardiac event 8 12 11 16 16 19
Recurrent cardiac events‡ 30 (57%) 46 (67%) 14 (54%) 41 (71%) 0 2 (33%)
Median cardiac event rate‡ 0.15 0.14 0.08 0.12 0.03 0.09*
Aborted cardiac arrest or LQTS death 5 (5%) 10 (7%) 1 (1%) 11 (9%)* 1 (3%) 1 (3%)
*p  0.05 when comparing males versus females of the same LQTS type; †ECG parameters are reported for first ECGs recorded off beta-blockers during specific age groups
in family members while excluding probands; numbers of carriers with ECGs recorded 15 years and at age 16–40 years are provided (subjects with first ECG recorded after
age 40 are not included), patients without ECGs recorded off beta-blockers during respective age periods are not included in the analysis. Welsh t tests were used for testing;
‡Recurrent cardiac events and cardiac event rates per patient per year were calculated only in patients who survived first cardiac event: 53 LQT1 males, 69 LQT1 females, 26
LQT2 males, 58 LQT2 females, 7 LQT3 males, and 6 LQT3 females, individual cardiac event rates were capped at the level of five cardiac events per patient per year. Wilcoxon
rank-sum tests were used for continuous variables and chi-square tests for binary variables.
ECG  electrocardiographic; LQTS  long QT syndrome. Other abbreviations as in Abbreviations box.
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Figure 1. Cumulative probability of the first cardiac event in long QT
syndrome carriers age  15 years by gender and genotype. P value is
computed based on multivariate Cox model. Observation time censored at
age 16 years. Numbers of males and females at risk are provided. See
Abbreviations box for definitions.
Figure 2. Cumulative probability of the first cardiac event in long QT
syndrome carriers age 16 to 40 years by gender and genotype, conditional
on no cardiac event before age 16. P value is computed based on
multivariate Cox model. Observation time is 16 to 40 years. Numbers of
males and females at risk are provided. See Abbreviations box for
definitions.
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or females (Fig. 1). The results of the analyses were very
similar when using first cardiac event regardless of beta-
blocker use (not shown).
Cardiac events in LQTS carriers age 16 to 40 years. There
were 68 patients with first cardiac event before beta-blocker
treatment among 274 LQTS carriers who survived to age 16
without any cardiac events. Figure 2 shows the cumulative
probability of a first cardiac event, conditional on survival to
age 16 without event, in female versus male LQTS carriers
age 16 to 40 years by genotype. The right panel of Table 3
shows HRs for females versus males, adjusted for QTc
duration in the same groups. Compared with males, females
had a significantly higher risk of first cardiac event among
both LQT1 and LQT2 carriers, but not LQT3 carriers.
When comparing by genotype (and confined to patients
without events before age 16), the cumulative probability of
first cardiac event between age 16 and 40 years was 48% in
LQT2 females, 31% in LQT1 females, and 10% to 20% in
LQT1 males, LQT2 males, and LQT3 males and females
(Fig. 2). The results of the analyses were very similar when
using first cardiac event regardless of beta-blocker use (not
shown).
Recurrent cardiac events in LQTS carriers. The analysis
of recurrent cardiac events and severity of clinical course was
conducted in LQTS carriers who had survived their first
cardiac event (Table 2): 122 (51%) LQT1 carriers, 84 (42%)
LQT2 carriers, and 13 (16%) LQT3 carriers. There were no
significant differences in the risk of recurrent cardiac events
before beta-blocker treatment between males and females in
all three genetic LQTS types. Cardiac event rates per
patient per year were not significantly different between
males and females in LQT1 and LQT2 carriers and were
higher in LQT3 females than males. This analysis was not
performed separately in age groups  and 15 years
because the numbers of symptomatic patients per age-
subgroup were limited.
Sudden death and lethality of cardiac events in family
members from genotyped LQTS families. Table 4 shows
cardiac events and sudden death (presumably LQTS death)
in all directly related family members from families with
known genotype, regardless of ECG recording or genetic
testing, therefore including both affected and unaffected
family members from the side of a family with LQTS
genetically confirmed. The occurrence of at least one cardiac
event and recurrent cardiac events were higher in male and
female LQT1 family members and in female LQT2 family
members than in male LQT2 family members and male and
female LQT3 family members. The total number of cardiac
events was much higher in female LQT1 and LQT2 family
members than in all other groups, indicating a higher risk of
recurrent cardiac events in these two subsets.
There were 84 sudden deaths before age 40 years in
directly related family members. In childhood, the occur-
rence of death was somewhat higher in male than female
LQT1 family members, whereas it was similarly low in
males and females from LQT2 and LQT3 families. In
Table 3. Relative Hazards of First Cardiac Event by LQTS Genotype and Age
533 LQTS Carriers Age 0–15 Years
274 LQTS Carriers Age 16–40
Years Without Prior Events
HR (95% CI)† p Value† HR (95% CI)† p Value†
Females vs. Males
LQT1 0.58 (0.40, 0.84) 0.005 3.35 (1.40, 8.02) 0.007
LQT2 0.73 (0.43, 1.25) 0.252 3.71 (1.37, 10.07) 0.010
LQT3 1.84 (0.47, 7.25) 0.384 0.90 (0.29, 2.82) 0.854
QTc* 1.07 (1.04, 1.11)  0.001 1.08 (1.08, 1.12)  0.001
Models based on stratified (by LQT type) Cox proportional hazards models, adjusted for QTc, with 165 first cardiac events in
533 persons through age 15 and 68 first cardiac events in 274 persons without cardiac events before age 16. *HR for a 10 ms
increase in QTc value; †Confidence intervals and p values have been adjusted for the weak within-family dependence via grouped
jackknife robust variance estimation (15).
CI  confidence interval; HR  hazards ratio; LQTS  long QT syndrome. Other abbreviations as in Abbreviations box.
Table 4. Cardiac Events and Sudden Death in LQTS Family Members by Family Genotype and Gender
LQT1 LQT2 LQT3
Males
(n  516)
Females
(n  559)
Males
(n  453)
Females
(n  523)
Males
(n  173)
Females
(n  151)
Median follow-up time (yrs) 24 27 25 27 25 20
Cardiac events
Family members with 1 104 (20%) 125 (22%) 67 (15%) 134 (26%)* 22 (13%) 20 (13%)
Family members with 2 53 (10%) 70 (13%) 29 (7%) 75 (15%)* 6 (4%) 8 (5%)
Total number of cardiac events 403 897 172 1062 37 40
Death
At age 0–15 yrs 16 (3%) 6 (1%)* 2 (1%) 1 (1%) 3 (2%) 1 (1%)
At age 16–40 yrs 3 (1%) 13 (3%) 8 (2%) 21 (5%) 4 (3%) 6 (4%)
*p  0.05 when comparing males versus females of the same LQTS type using chi-square test.
LQTS  long QT syndrome. Other abbreviations as in Abbreviations box.
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adulthood, the occurrence of death was higher in female
than male LQT2 family members. However, the lethality of
cardiac events was higher in males than females from either
LQT1 or LQT2 families (Fig. 3). The lethality of cardiac
events in male and female LQT3 family members was
similar, but was significantly higher than in LQT1 and
LQT2 families.
DISCUSSION
In this study, we found that the LQTS genotype influences
the probability of cardiac events differently in male and
female children and adult LQTS patients, indicating a
genotype-specific modulating effect of age and gender
primarily in LQT1 and LQT2, but not in LQT3 patients.
During childhood, the risk of cardiac events was signifi-
cantly higher in LQT1 males than in LQT1 females. In
LQT2 and LQT3 children, there was no significant differ-
ence between males and females in the risk of cardiac events.
When comparing the risk of cardiac events by genotype and
gender during childhood, LQT1 males were the group at
highest risk with a 56% cumulative probability of a cardiac
event by age 15 years, independently of QTc duration;
LQT1 females had a 40% risk, whereas LQT2 males and
females had a 30% risk of experiencing cardiac events by age
15 years; LQT3 children had a low risk of cardiac events.
Among adults who remained event-free until age 16,
LQT2 and LQT1 females had a significantly increased risk
of cardiac events compared with males of the same geno-
type, again, independently of QTc duration; LQT1 and
LQT2 males and LQT3 females and males, who survived
until age 16 without events, had a lower risk of cardiac
events, unless they presented with a substantial QTc pro-
longation. This analysis demonstrates that the hazard of
cardiac events diminishes substantially with age in LQT1
and LQT2 males, and also decreases somewhat in LQT1
females. In LQT2 females, there is an increased risk of
cardiac events both during childhood and adulthood. Al-
though the overall number of cardiac events in LQT3
patients was small, there was no trend toward age- and
gender-dependency of the risk in these patients. The above
findings indicate that vulnerability to cardiac events changes
primarily with age in LQTS males with potassium channel
gene abnormalities. The risk of cardiac events in LQTS
females with potassium channel genes mutations remains
increased both during childhood and adulthood. Impor-
tantly, the above analyses showed similar results when using
first cardiac event regardless of beta-blocker use.
Recurrent cardiac events are most prevalent in LQT1 and
LQT2 females with simultaneous low lethality of cardiac
events in these two groups indicating a high likelihood of
self-terminating episodes of torsades de pointes. The lethal-
ity of cardiac events is the highest in LQT3 males and
females (19% and 18%, respectively), and higher in LQT1
males than females (5% vs. 2%, respectively) and in LQT2
males than females (6% vs. 2%, respectively).
The effectiveness of beta-blocker therapy in LQTS pa-
tients was the subject of our prior study (14) in which we
demonstrated that in about 70% of patients beta-blockers
are effective in preventing subsequent cardiac events whereas
cardiac events continue to occur in the remaining 30%
despite beta-blocker treatment. In that paper we also ana-
lyzed the effectiveness of beta-blockers by genotype and
found that beta-blockers are associated with a significant
reduction in cardiac event occurrence and rates in LQT1
and LQT2 patients. There was, however, a trend for a better
effectiveness of beta-blockers in LQT1 than in LQT2
patients. We did not perform an analysis of the effectiveness
of beta-blockers by age, gender, and genotype in this paper
because we have limited statistical power to carry out such
an analysis in so many subgroups.
The overall age-related decrease in the risk of cardiac
events in LQT1 and LQT2 males does not have a clear
explanation. It is likely that increased levels of androgens
and decreased heart rate after puberty contribute to this
Figure 3. The lethality of cardiac events analyzed by sex in long QT syndrome (LQTS) family members with known genotype. Open bars  males; black
bars  females. p  0.001 when comparing LQT3 males and females to LQT1 and LQT2 males and females, respectively. For abbreviations see
Abbreviations box.
108 Zareba et al. JACC Vol. 42, No. 1, 2003
Effect of Age and Gender in LQTS July 2, 2003:103–9
phenomenon (16). Because there is no evidence for gender-
related differences in the risk of cardiac events in LQT3
adults, it is likely that male (and/or female) hormones
modulate function of potassium, but not sodium channels.
Simultaneously, the concept of decreased density of
potassium currents in the myocardium of females, as ob-
served in animal models (17), seems to provide a plausible
explanation for gender-related differences in propensity to
cardiac events among patients carrying IKr or IKs channel
gene mutations. Higher lethality of cardiac events in LQT3
males and females could be attributed to increased trans-
mural heterogeneity of repolarization observed in pharma-
cological models of sodium channel dysfunction (18). It is
possible that a higher lethality of cardiac events in LQT1
and LQT2 males than LQT1 and LQT2 females is related
to a generally slower heart rate in adult males, eventually
precipitating more non–self-terminating torsades de
pointes.
These gender- and age-related differences in clinical
course of the disease are accompanied by sex- and age-
related differences in QTc duration and heart rate. Al-
though previous studies showed significantly longer QTc
duration in adult LQTS females than males (7–11), we
could confirm these previous findings only in LQT2 carri-
ers, but not in LQT1 and LQT3 carriers. In fact, LQT1
children showed longer QTc duration than LQT1 adults
regardless of gender.
Long QT syndrome patients who were event free until
age 16 years may represent a more benign course of the
disease in adulthood. However, our data demonstrate that
the clinical course is not homogenous in various genetic
types of LQTS stratified by age and gender. The 48%
cumulative probability of cardiac events in LQT2 females
between age 16 and 40 years is higher or comparable to the
cumulative probability of cardiac events in most LQTS
children except LQT1 males who show a higher (56%) risk.
We believe that this observation is of major importance and
emphasizes a need to carefully follow and treat adult LQTS
patients (particularly females) who remain at high risk of
cardiac events despite asymptomatic course in childhood
and adolescence. The differences in the clinical course of
LQTS are most likely determined by genetic background of
the disorder and by different penetrance of the disease even
inside the same family carrying the same mutation, as
demonstrated by Priori et al. (19). Some additional causative
conditions (e.g., varying degree of repolarization heteroge-
neity in the myocardium) and modulating factors (e.g.,
varying susceptibility to sympathetic activation) might op-
erate in LQTS carriers who, despite ion channel gene
mutation and prolonged QTc, do not develop cardiac
events.
Our findings that the risk of cardiac events and lethality
of cardiac events vary depending on age and gender in
different genetic types of LQTS, and observations on age-
and gender-related differences in QTc duration, indicate
differential modulating effects of age and gender on the
clinical manifestation of LQTS.
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